Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Shanghai Unicar-Therapy Bio-medicine Technology
Alternative Names: CD19-CAR-T-Shanghai-Youkadi-Biomedical-Technology; ssCART-19 cell therapyLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Shanghai Unicar-Therapy Bio-medicine Technology
- Developer Shanghai Unicar-Therapy Bio-medicine Technology; Soochow University; The Third Xiangya Hospital of Central South University
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma
- Phase I/II Acute myeloid leukaemia; Multiple myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase I Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 16 Apr 2024 Shanghai Unicar-Therapy Bio-medicine Technology plans a phase II trial in Precursor cell lymphoblastic leukaemia lymphoma (Recurrent, Second-line therapy or greater) in China (IV) in April 2024 (NCT06367114)
- 09 Dec 2023 Efficacy and adverse events data from phase-I trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from phase I/II trial in in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2023)